- Home
- LX vs HURA Comparison
LX vs HURA Comparison
Compare LX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LX | HURA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 160.5M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LX | HURA |
|---|---|---|
| Price | $0.80 | $2.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 5.5M | 247.2K |
| Earning Date | 05-20-2026 | 05-15-2026 |
| Dividend Yield | ★ 18.73% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.41 |
| 52 Week High | $5.94 | $3.43 |
Technical Indicators
Market Signals| Indicator | LX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 16.71 | 44.21 |
| Support Level | N/A | $2.01 |
| Resistance Level | $2.06 | $2.24 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.64 | 17.86 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.